Comparative pharmacology and abuse potential of oral dexamphetamine and lisdexamfetamine—A literature review
Author:
Open Access
- 18 July 2024
- journal article
- review article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 39 (6) , e2910
Abstract
Objective: To compare the pharmacology and abuse potential of oral dexamphetamine and lisdexamfetamine (LDX).Methods: A search of Medline and Embase was conducted to identify relevant articles for this literature review.Results: Dexamphetamine and LDX, a prodrug of dexamphetamine, are indicated for the treatment of attention‐deficit/hyperactivity disorder. It has been suggested that LDX may have a reduced potential for oral abuse compared to immediate‐release dexamphetamine. As a prodrug, LDX has the same pharmacodynamic properties as dexamphetamine. A study in healthy adults showed that the pharmacokinetic profile of dexamphetamine following oral administration of LDX is essentially identical to that of an equimolar dose of dexamphetamine administered 1 h later. In addition, dexamphetamine produced subjective drug liking effects comparable to those produced by LDX. LDX showed linear dose proportional pharmacokinetics up to a dose of 250 mg, indicating a lack of overdose protection at supratherapeutic doses. Furthermore, the exposure to dexamphetamine released from LDX may be prolonged by the consumption of alkalizing agents.Conclusions: The available evidence from pharmacodynamic, pharmacokinetic and abuse liability studies suggests a comparable potential for oral abuse of dexamphetamine and LDX.Keywords
This publication has 45 references indexed in Scilit:
- A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjectsNeuropsychopharmacology Reports, 2019
- Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover studyClinical Therapeutics, 2010
- Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoproteinEuropean Journal of Pharmacology, 2008
- Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom StudyBiological Psychiatry, 2007
- Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2European Journal of Pharmacology, 2007
- Oral D‐amphetamine causes prolonged displacement of [11C]raclopride as measured by PETSynapse, 2003
- Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levelsSynapse, 1993
- Plasma levels of d-amphetamine in hyperactive childrenPsychopharmacology, 1979
- Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pHClinical Pharmacology & Therapeutics, 1978
- Pharmacokinetic and clinical studies on amphetamine dependent subjectsEuropean Journal of Clinical Pharmacology, 1970